scholarly journals Dasatinib-Induced Rhabdomyolysis in a 33-Year-Old Patient with Chronic Myeloid Leukemia

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Andrew Stevenson Joel Chandranesan ◽  
Samip Master ◽  
Olivia Antosz ◽  
Breanne PeytonThomas ◽  
Nebu Koshy
Keyword(s):  
Skeletal Muscle ◽  
Human Immunodeficiency Virus ◽  
Chronic Myeloid Leukemia ◽  
Side Effect ◽  
Myeloid Leukemia ◽  
Newly Diagnosed ◽  
Immunodeficiency Virus ◽  
Life Threatening ◽  
Crush Injuries

Rhabdomyolysis is a life-threatening syndrome due to breakdown of the skeletal muscle. It can be caused by massive trauma and crush injuries or occur as a side effect of medications. Here, we describe a case of a 33-year-old male with human immunodeficiency virus (HIV) and newly diagnosed chronic myeloid leukemia (CML) with severe life-threatening rhabdomyolysis due to a rare offending agent.

Human immunodeficiency virus infection and chronic myeloid leukemia

2012 ◽  
Vol 36 (11) ◽  
pp. 1334-1338 ◽  
Author(s):  
Moosa Patel ◽  
Vinitha Philip ◽  
Fatima Fazel ◽  
Atul Lakha ◽  
Alexander Vorog ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Chronic Myeloid Leukemia ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Myeloid Leukemia ◽  
Immunodeficiency Virus

scholarly journals Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Leukemia ◽  
2021 ◽  
Author(s):  
Hagop M. Kantarjian ◽  
Timothy P. Hughes ◽  
Richard A. Larson ◽  
Dong-Wook Kim ◽  
Surapol Issaragrisil ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Survival Rates ◽  
Chronic Phase ◽  
Individual Treatment ◽  
Molecular Response ◽  
Newly Diagnosed ◽  
Long Term Outcomes ◽  
Treatment Free Remission

AbstractIn the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death, and increased eligibility for treatment-free remission (TFR). Cumulative 10-year rates of MMR and MR4.5 were higher with nilotinib (300 mg twice daily [BID], 77.7% and 61.0%, respectively; 400 mg BID, 79.7% and 61.2%, respectively) than with imatinib (400 mg once daily [QD], 62.5% and 39.2%, respectively). Cumulative rates of TFR eligibility at 10 years were higher with nilotinib (300 mg BID, 48.6%; 400 mg BID, 47.3%) vs imatinib (29.7%). Estimated 10-year overall survival rates in nilotinib and imatinib arms were 87.6%, 90.3%, and 88.3%, respectively. Overall frequency of adverse events was similar with nilotinib and imatinib. By 10 years, higher cumulative rates of cardiovascular events were reported with nilotinib (300 mg BID, 16.5%; 400 mg BID, 23.5%) vs imatinib (3.6%), including in Framingham low-risk patients. Overall efficacy and safety results support the use of nilotinib 300 mg BID as frontline therapy for optimal long-term outcomes, especially in patients aiming for TFR. The benefit-risk profile in context of individual treatment goals should be carefully assessed.

scholarly journals Non-Hodgkin’s Plasmablastic Lymphoma as Initial Presentation of Human Immunodeficiency Virus

2021 ◽  
Vol 9 ◽  
pp. 232470962110146
Author(s):  
Roopam Jariwal ◽  
Nadia Raza ◽  
Janpreet Bhandohal ◽  
Everardo Cobos
Keyword(s):  
Human Immunodeficiency Virus ◽  
Acquired Immunodeficiency Syndrome ◽  
Initial Presentation ◽  
Plasmablastic Lymphoma ◽  
Healthy Male ◽  
Immunodeficiency Virus ◽  
Life Threatening ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Head Neck

Plasmablastic lymphoma (PBL) is a subtype of non-Hodgkin’s lymphoma that manifests in patients with the diagnosis of human immunodeficiency virus (HIV), more prominently in the head, neck, and oral mucosal region. The diagnosis of this rare lymphoma serves as a concomitant diagnosis of acquired immunodeficiency syndrome. The case is of a 33-year-old previously healthy male, with an unknown diagnosis of HIV with a painful right mandibular mass. He was subsequently diagnosed with PBL and HIV. This case of PBL illustrates the importance of linking a rare and potentially life-threatening diagnosis as a possible first manifestation of HIV.

scholarly journals Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

Haematologica ◽  
2009 ◽  
Vol 95 (6) ◽  
pp. 914-921 ◽  
Author(s):  
W. Deenik ◽  
J. J. W. M. Janssen ◽  
B. van der Holt ◽  
G. E. G. Verhoef ◽  
W. M. Smit ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Newly Diagnosed
Sign in / Sign up

Export Citation Format

Share Document